FIG. 1

Normal Secretory Total Serum Testosterone Profiles in Healthy Young and Older Men





FIG. 2





Serum Testosterone (ng/dl) +/-SE
0
200
400
600
800
1000
1200
1400
11/3/01
12/5/01
12/10/01
12/15/01
12/20/01
12/25/01
12/30/01
Date
START
END
CLO
ENCLO
ZUCLO

FIG. 3

FIG. 4



120
115
110
105
100
95
90
85
80
Total Cholesterol
Day 0
Day 12
Enclomid
Clomid
Zuclomid

FIG. 5



700
600
500
400
300
200
100
0
baseline
day 1
day 15
follow-up
Serum Total T (ng/dl)
Enc @ 12.5
Enc @ 25
Enc @ 50
Androgel 1% (5G)
Androgel 1%(10G)
Placebo
Treatment

FIG. 6



Effect of Treatment on Serum LH
LH mIU/ml.
12
10
8
6
4
2
0
day1
day 15
follow-up
Enc @12.5
Enc @25.0
Enc @50.0
Androgel1% 5G
Androgel1% 10G
Placebo

FIG. 7




Effect of Treatment on Serum FSH
FSH mIU/mL
12
10
8
6
4
2
0
day1
day 15
follow-up
Enc @12.5
Enc @25.0
Enc @50.0
Androgel1% 5G
Androgel1% 10G
Placebo

FIG. 8



EP300 = BMI>26, Glu >99, T<300
Otherwise = BMI<27, Glu <100, T<300
EP300 vs. Otherwise p<0.0001 for all treatments

FIG. 9




Change in Serum Glucose From Baseline in Androxal™ Treatment Group Subpopulations
10
5
0
-5
-10
-15
-20
-25
P 0.049
P 0.1
P 0.17
P 0.3
P 0.24
P 0.001
P 0.011
P 0.002
P 0.045
P 0.19
Mo 1
Mo 2
Mo 3
Mo 4.5
Mo 6
Otherwise
EP300
EP300 = BMI>26, Glu >99, T<300
Otherwise = BMI<27, Glu <100, T<300

FIG. 10


Change in Serum Glucose From Baseline in
Androgel and Placebo EP300 Subpopulations
No significant differences from baseline
10
8
6
4
2
0
-2
-4
-6
-8
Mo 1
Mo 2
Mo 3
Mo 4.5
Mo 6
Androgel
Placebo
EP300 = BMI>26, Glu >99, T<300